Emergent BioSolutions (NYSE: EBS)
Emergent BioSolutions Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Emergent BioSolutions Company Info
Emergent BioSolutions makes the only FDA-approved anthrax vaccine.
News & Analysis
Why Emergent BioSolutions Stock Is Skyrocketing Today
Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump.
Why Emergent BioSolutions Stock Is Tumbling Today
The healthcare stock will soon be booted from an index tracked by several ETFs.
Why Emergent BioSolutions Stock Dived by 9% Today
Investors didn't greet news of the CEO's departure warmly.
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Both of these stocks have plummeted more than 50% over the past year.
Is Emergent BioSolutions Stock a Buy Now?
The deluge of bad news seems to be over, and a recovery could be in the works.
Down 75%, Can Emergent BioSolutions Turn Things Around?
Has the stock finally bottomed out?
Why Emergent BioSolutions Stock Inched Slightly Higher Today
Investors approved, if not enthusiastically, their company's latest asset sale.
Why Emergent BioSolutions Stock Is Soaring Today
Emergent received a key approval from the FDA, but just how good is this news?
Valuation
Earnings Transcripts
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
EBS earnings call for the period ending June 30, 2024.
Emergent BioSolutions (EBS) Q1 2024 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2024.
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2023.
Emergent BioSolutions (EBS) Q3 2023 Earnings Call Transcript
EBS earnings call for the period ending September 30, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.